Dupixent Denied by Insurance? How to Appeal

Dupixent (dupilumab, NDC: 00024-5916-01 for 300 mg/2 mL; 00024-5917-01 for 200 mg/1.14 mL) is one of the most prescribed and most denied specialty biologics in the US. At $40,000–$50,000 per year, insurers use aggressive Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization, step therapy, and medical necessity criteria to block access. If your Dupixent has been denied, you have strong grounds to fight back.

Why Insurers Deny Dupixent

Step therapy failure. Insurers require you to try and fail cheaper alternatives first — typically topical corticosteroids (TCS), tacrolimus or pimecrolimus (for atopic dermatitis), or inhaled corticosteroids and LABAs (for asthma) — before approving Dupixent.

Severity thresholds not documented. Plans require documented moderate-to-severe disease using validated standardized scoring. For atopic dermatitis: IGA ≥3, EASI ≥16, or SCORAD ≥25. For asthma: uncontrolled persistent asthma on medium-dose ICS. If your chart does not contain these documented scores, the PA will be denied.

Off-label use claim. Dupixent has FDA approvals for six indications. Denials for any FDA-approved indication should be challenged; denials for off-label use require a different argument (clinical necessity, compendia support).

Lab criteria not met. Blood eosinophil count thresholds are used as gatekeeping criteria for the asthma indication (≥150 cells/µL) and the COPD indication (≥300 cells/µL).

"Alternatives not tried." Even within the biologic class, plans may compare Dupixent to other approved agents and require justification for dupilumab specifically.

FDA-Approved Indications for Dupixent

Dupixent (dupilumab) blocks IL-4 and IL-13, the key drivers of Type 2 inflammation. Current FDA-approved indications:

• Moderate-to-severe atopic dermatitis (eczema): Age 6 months and older when disease is not adequately controlled with topical therapies
• Moderate-to-severe asthma with eosinophilic phenotype: Age 6 and older, or oral corticosteroid-dependent asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP): Age 12 and older as add-on maintenance therapy
• Eosinophilic esophagitis (EoE): Age 1 and older weighing ≥15 kg, when disease is not controlled with dietary changes
• Prurigo nodularis: Adults with inadequate control from topical therapies
• COPD with eosinophilic phenotype: Adults with FEV₁ <70% and blood eos ≥300 cells/µL

Clinical Guidelines That Support Your Appeal

American Academy of Dermatology (AAD) Guidelines: Recommend dupilumab as a first-line systemic agent for moderate-to-severe atopic dermatitis not controlled by topical therapy. Grade A, Level I evidence.

Global Initiative for Asthma (GINA) Strategy Report: Dupilumab is a recommended add-on biologic therapy for severe Type 2 asthma with allergic or eosinophilic phenotype.

EPOS 2020 (European Position Paper on Rhinosinusitis and Nasal Polyps): Biologics including dupilumab are recommended for severe CRSwNP refractory to surgery and intranasal corticosteroids.

American College of Allergy, Asthma and Immunology (ACAAI): Supports dupilumab for both atopic dermatitis and asthma per published practice parameters.

Step-by-Step Appeal

Step 1: Document disease severity with validated scores.

For atopic dermatitis, your appeal must include objective severity scores:

• IGA (Investigator Global Assessment): Moderate = 3, Severe = 4
• EASI (Eczema Area and Severity Index): Moderate ≥16, Severe ≥21
• SCORAD: Moderate ≥25, Severe ≥50
• DLQI (Dermatology Life Quality Index): Large effect ≥11
• Peak Pruritus NRS: Score 7–10 indicates severe disease

Your dermatologist should document these scores in both the PA request and the appeal.

Step 2: Document failure of required prior therapies.

Show you have tried what the insurer requires, with dates, doses, duration, and outcomes:

• Topical corticosteroids (moderate- and high-potency) for at least 4 weeks
• Calcineurin inhibitors (tacrolimus, pimecrolimus) if appropriate for the patient's age and disease location
• Systemic immunosuppressants if required (methotrexate, cyclosporine, azathioprine) — document failure or contraindication
• Phototherapy — document why not feasible if that is the case (no local access, schedule constraints, photosensitivity)

Step 3: Invoke your state's step therapy override law.

As of 2026, 45+ states have enacted step therapy reform legislation. Most require an override when:

1. The required drug was already tried and failed
2. The required drug is contraindicated or clinically inappropriate for this patient
3. The patient has been previously stabilized on the requested drug
4. Requiring the step therapy drug would cause harm

Cite your state's specific statute by name in the appeal letter.

Step 4: Request peer-to-peer review.

Request a peer-to-peer call between your dermatologist or allergist and the insurer's medical reviewer. This physician-to-physician conversation overturns denials significantly more often than written appeals alone.

Step 5: File for External Independent Review: Complete Guide" class="auto-link">external review if internal appeal fails.

External reviews of Dupixent denials have high overturn rates when the clinical criteria are met and the severity scores are documented.

Sample PA Appeal Letter Language

"I am appealing the denial of Dupixent (dupilumab) [dose and frequency] for [indication]. My [dermatologist/allergist], Dr. [Name], has determined that Dupixent is medically necessary based on documented disease severity (IGA [score], EASI [score]) and prior failure of [list prior therapies with dates and doses].

Per AAD Clinical Guidelines (2023), dupilumab is the recommended first-line systemic therapy for moderate-to-severe atopic dermatitis not controlled with topical therapy (Grade A, Level I evidence). Per [State] Step Therapy Override Law [cite statute and section], I request an immediate exception to step therapy requirements because [reason]. I respectfully request reversal of this denial and authorization of Dupixent (NDC: 00024-5916-01)."

Documentation Checklist

• Denial letter with specific criteria cited
• Validated severity scores (IGA, EASI, SCORAD, DLQI)
• Dermatologist/allergist letter with medical necessity justification
• Treatment history: prior therapies with dates, doses, duration, outcomes
• Insurer's clinical policy bulletin for Dupixent
• State step therapy override law citation
• Eosinophil count (for asthma or COPD indication)
• Photography of affected skin (for atopic dermatitis) if available

Patient Assistance if Appeal Fails

• Dupixent MyWay Copay Card: Eligible commercially insured patients may pay as little as $0/month
• Sanofi Patient Assistance Program: For uninsured or underinsured patients
• NeedyMeds.org / RxAssist: Patient assistance program directories

Fight Back With ClaimBack

Dupixent denials require severity score documentation, step therapy law arguments, and indication-specific clinical criteria — all in one letter. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal